LOW EXPRESSION OF NIBRIN PREDICTS BETTER PROGNOSIS IN PATIENTS WITH OVARIAN CANCER TREATED WITH TRABECTEDIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD)

被引：0
|
作者：
Aracil, M. [1 ]
Nieto, A. [1 ]
Tanovic, A. [2 ]
Monk, B. J. [3 ]
Kaye, S. B. [4 ]
Poveda, A. [5 ]
Herzog, T. J. [6 ]
Parekh, T. [7 ]
Badri, N. [2 ]
Galmarini, C. M. [1 ]
机构：
[1] PharmaMar, Dept Res & Dev, Madrid, Spain
[2] PharmaMar, Med Affairs, Madrid, Spain
[3] St Josephs Hosp, Creighton Univ Sch Med, Div Gynecol Oncol, Phoenix, AZ USA
[4] Royal Marsden Hosp, Dept Canc Med, Sutton, Surrey, England
[5] Valencian Inst Oncol, Dept Gynecol Oncol, Valencia, Spain
[6] Columbia Univ Coll Phys & Surg, Div Gynecol Oncol, New York, NY 10032 USA
[7] Janssen LLC, Dept Res & Dev, Raritan, NJ USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2013年 / 23卷 / 08期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Final survival results of the randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer
    Monk, B. J.
    Herzog, T. J.
    Kaye, S. B.
    Krasner, C. N.
    Vermorken, J. B.
    Muggia, F.
    Pujade-Lourraine, E.
    Zintl, P.
    Parekh, T. V.
    Poveda, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] CA-125 Response Patterns in Patients With Recurrent Ovarian Cancer Treated With Pegylated Liposomal Doxorubicin (PLD)
    Oaknin, Ana
    Barretina, Pilar
    Perez, Xavier
    Jimenez, Laura
    Velasco, Montserrat
    Alsina, Maria
    Brunet, Joan
    Ramon Germa, Josep
    Beltran, Miguel
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2010, 20 (01) : 87 - 91
  • [23] Implications of BRCA mutations on recurrent ovarian cancer outcome treated with pegylated liposomal doxorubicin (PLD)
    Safra, Tamar
    Borgato, Lucia
    Nicoletto, Maria Ornella
    Donach, Martin Edward
    Rolnitzky, Linda
    Geva, Ravit
    Peles, Sharon
    Pua, Thara
    Novetsky, Akiva
    Gabizon, Alberto
    Muggia, Franco
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [24] A European, Observational, Prospective Trial of Trabectedin Plus Pegylated Liposomal Doxorubicin in Patients with Platinum-Sensitive Ovarian Cancer
    Pignata, Sandro
    Scambia, Giovanni
    Villanucci, Alessandro
    Naglieri, Emanuele
    Ibarbia, Mikel Arruti
    Brusa, Federica
    Bourgeois, Hugues
    Sorio, Roberto
    Casado, Antonio
    Reichert, Dietmar
    Dopchie, Catherine
    De Rivas, Beatriz
    de Sande, Luis Miguel
    ONCOLOGIST, 2021, 26 (04): : E658 - E668
  • [25] Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer
    Jones, Robin L.
    Herzog, Thomas J.
    Patel, Shreyaskumar R.
    von Mehren, Margaret
    Schuetze, Scott M.
    Van Tine, Brian A.
    Coleman, Robert L.
    Knoblauch, Roland
    Triantos, Spyros
    Hu, Peter
    Shalaby, Waleed
    McGowan, Tracy
    Monk, Bradley J.
    Demetri, George D.
    CANCER MEDICINE, 2021, 10 (11): : 3565 - 3574
  • [26] Trabectedin plus pegylated liposomal doxorubicin: retrospective analysis in heavily pretreated platinum-sensitive ovarian cancer
    Nicoletto, Maria Ornella
    Baldoni, Alessandra
    Casarin, Alessandra
    Randon, Giovanni
    Nardin, Margherita
    Baretta, Zora
    Lardelli, Pilar
    Nieto, Antonio
    Alfaro, Vicente
    Rigamonti, Claudia
    Conte, Pier Franco
    TUMORI, 2015, 101 (05) : 506 - 510
  • [27] Tolerability of long-term use of trabectedin (Tr) in combination with pegylated liposomal doxorubicin (PLD) in patients (pts) with relapsed ovarian cancer (ROC)
    Romero, I.
    Colombo, N.
    Kaye, S. B.
    Arranz, J.
    Roszak, A.
    Provencher, D. M.
    Santabarbara, P.
    Bayever, E.
    Almorin, E.
    Muggia, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] EARLY CA-125 RESPONSE PATTERN IN PATIENTS WITH RECURRENT OVARIAN CANCER TREATED WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD)
    Oaknin, A.
    Barretina, P.
    Jimenez, L.
    Perez, X.
    Velasco, M.
    Alsina, M.
    Pardo, B.
    Brunet, J.
    Germa, J. R.
    Beltran, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 215 - 215
  • [29] Efficacy and safety of generic pegylated liposomal doxorubicin (PLD) in relapsed ovarian cancer
    Ghosh, I.
    Dwary, A.
    Dabkara, D.
    Bhaumik, J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S731 - S731
  • [30] TRABECTEDIN MONOTHERAPY AND IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN TO TREAT HEAVILY-TREATED PATIENT WITH RELAPSED OVARIAN CANCER
    Miah, S.
    Tahir, S.
    Lofts, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1440 - 1440
12345